Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 16;19:13. doi: 10.1186/s12860-018-0160-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — Pre-treatment, higher concentration of EGTA, and actin depolymerization does not change CpnF binding to membranes. a Cells expressing GFP-CpnF and CpnF-GFP were either disrupted in the presence of EGTA and calcium (pre-treatment) or disrupted and then treated with EGTA (10 mM) and calcium (2 mM). All membranes were pelleted by ultracentrifugation. The supernatant samples (S) and pelleted membranes samples (P) were analyzed by Western blot with an antibody to GFP. b Cells expressing GFP-CpnF were treated with Latrunculin A (LatA) or DMSO (control) for 30 min prior to disruption. All membranes were pelleted by ultracentrifugation. The supernatant samples (S) and pelleted membranes samples (P) were analyzed by Western blot with an antibody to GFP (α-GFP) and an antibody to actin (α-actin)